Clinical Trial Update: CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma [NA]

View source ↗

Summary

A CD30-targeted CAR-T therapy is being studied for CD30-positive relapsed/refractory lymphoma. The trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• CD30 CAR-T therapy

Snippet

Sponsor: Shanxi Bethune Hospital | Conditions: Lymphoma, B-Cell | NA | Status: RECRUITING